{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:17:01Z","timestamp":1791897421640,"version":"4.3.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The mortality ratio in patients with acromegaly has improved over the last few decades. We aimed to determine the mortality rate and correlated factors in patients with acromegaly before and after the introduction of national protocols for treatment. In addition, we determined whether there are sex-related differences in mortality of patients with acromegaly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This observational retrospective study included 399 consecutive patients with acromegaly between January 2001\u2013December 2022. Paraclinical data included random growth hormone (GH) and insulin-like growth factor-I (IGF1) levels, maximal pituitary tumor diameter at diagnosis, first visit, and last evaluation. Standardized mortality ratio (SMR) was calculated by dividing the observed and expected mortality rates. Cox regression analysis revealed the independent factors associated with mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the last visit, 31.07% (124) of patients were cured, 22.05% (88) had controlled acromegaly with medication, and 45.31% (181) had not controlled acromegaly. During follow-up (13.03 \u00b1 5.65 years, 5216.62 person-years), 89 patients died (0.017%), resulting in an SMR of 1.18 [95% CI 0.95\u20131.45]. The independent factors associated with mortality were the last IGF1 level\/last random GH level, absence of surgery, gonadotropin deficiency, and age. Patients with normal IGF1 after treatment showed an SMR of 0.71, whereas patients with IGF1 ratio &amp;gt; 1 showed SMR=1.51. Patients diagnosed between 1975\u20132007 and 2008\u20132022 had SMR = 1.25 [95% CI 0.97\u20131.58] and SMR = 1.09 [95% CI 0.68\u20131.65], respectively. In females with acromegaly, SMR was 1.63 [95% CI 1.24\u20132.11]; 1.76 [95% CI 1.30\u20132.34] in women diagnosed before 2008 and 1.33 [95% CI 0.69\u20132.33] in those diagnosed after 2008. Males with acromegaly had a mortality ratio similar to males from the general population (SMR = 0.99, [95% CI 0.66\u20131.41]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients diagnosed with acromegaly in the last 15 years had lower mortality rates than those diagnosed before 2008, due to the availability of new medications, primarily somatostatin receptor analogs and to a higher proportion of patients undergoing surgery. Females still have a high mortality ratio owing to older age at diagnosis and higher risk of metabolic complications. Therefore, efforts should be made for early diagnosis of acromegaly in women.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1348972","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:51:21Z","timestamp":1708494681000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["High mortality risk among women with acromegaly still persists"],"prefix":"10.3389","volume":"15","author":[{"given":"Simona","family":"G\u0103loiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iustin-Daniel","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa Isabella","family":"T\u0103nasie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"B\u0103rbulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionela","family":"Baciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Alexandru","family":"Niculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca Alexandra","family":"Trif\u0103nescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"C\u0103p\u0103\u0163\u00een\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eerban","family":"Radian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lina","family":"Poian\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03135.x","article-title":"Epidemiology of acromegaly in the Newcastle region","volume":"12","author":"Alexander","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2265.1994.tb03789.x","article-title":"Determinants of the clinical outcomes and survival in patients with acromegaly","volume":"41","author":"Rajasoorya","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1381","article-title":"A nationwide survey of mortality in patients with acromegaly","volume":"90","author":"Kauppinen-M\u00e4kelin","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in patients with acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"Meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in patients with acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed the guidelines of a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031584","article-title":"Growth hormone and pituitary radiotherapy but not serum insulin-like growth factor-I concentrations predicted excess mortality in patients with acromegaly","volume":"89","author":"Ayuk","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1097","article-title":"ACTH deficiency, high-dose hydrocortisone replacement, and radiotherapy were independent predictors of mortality in patients with acromegaly","volume":"94","author":"Sherlock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3697","article-title":"Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: A subanalysis from the Dutch National Registry of growth hormone Treatment in Adults","volume":"100","author":"Van Varsseveld","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4158\/EP161373.OR","article-title":"Predictors of quality of life in 165 patients with acromegaly: Results from a single-center study","volume":"23","author":"Kreitschmann-Andermahr","year":"2017","journal-title":"Endocr Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0521-6","article-title":"Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire","volume":"49","author":"Vandeva","year":"2015","journal-title":"Endocrine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: A 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.816426","article-title":"Acromegaly: clinical care in central and Eastern Europe, Israel, and Kazakhstan","volume":"13","author":"Bolanowski","year":"2022","journal-title":"Front Endocrinol"},{"key":"B14","unstructured":"Casa Na\u0163ional\u0103 de Asigur\u0103ri de S\u0103n\u0103tate. Ordinul 461\/477\/2010. Protocol terapeutic \u00een acromegalie. Monitorul Oficial al Rom\u00e2niei, Partea I, Num\u0103rul 386 bis2010"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2018.1527177","article-title":"Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC)","volume":"27","author":"Williams","year":"2018","journal-title":"Blood Press"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S002","article-title":"Classification and diagnosis of diabetes: Standards of medical care in diabetes\u20142022","year":"2022","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0509","article-title":"Mortality in acromegaly decreased in the last decade: A systematic review and meta-analysis","volume":"181","author":"Bolfi","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0015","article-title":"Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study","volume":"178","author":"Esposito","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03275-6","article-title":"Trends in incidence and mortality risk for acromegaly in Norway: A cohort study","volume":"80","author":"Falch","year":"2023","journal-title":"Endocrine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","article-title":"AcroBel - The Belgian registry on acromegaly: A survey of the \u201creal-life\u201d outcome in 418 acromegalic subjects","volume":"157","author":"Bex","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.193","article-title":"Pituitary gland: Mortality in acromegaly reduced with multimodal therapy","volume":"10","author":"Biermasz","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1675","article-title":"Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center","volume":"15","author":"Gheorghiu","year":"2016","journal-title":"Hormones (Athens)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2020.0020","article-title":"Improvement of acromegaly control with multimodal therapy in Romania","volume":"71","author":"Marinescu","year":"2020","journal-title":"Endokrynol Pol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2015.476","article-title":"Mortality of patients with acromegaly from a tertiary national neuroendocrine center","volume":"11","author":"G\u0103loiu","year":"2015","journal-title":"Acta Endocrinol (Bucharest)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: A nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13141","article-title":"ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centers","volume":"85","author":"O\u2019Reilly","year":"2016","journal-title":"Clin Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1348972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T05:51:23Z","timestamp":1708494683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1348972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":28,"alternative-id":["10.3389\/fendo.2024.1348972"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1348972","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"article-number":"1348972"}}